Best Stocks

Mangoceuticals, Inc. (NASDAQ:MGRX) announced the upcoming release of its second Mango ED product leveraging the Company’s existing custom compound alongside Sildenafil. MGRX is a company focused on developing, marketing, and selling multiple men’s health and wellness products through a secure telemedicine platform, including its uniquely formulated drug, “Mango”.

The launch of the Company’s Sildenafil based Mango ED product is scheduled to be available for purchase online this summer. Like the Company’s currently marketed and sold Tadalafil based Mango ED product, which leverages the same active ingredient found in Cialis™, the new Sildenafil-based Mango will still be compounded with Oxytocin and L-Arginine in a tasty Mango-flavored rapid dissolve tablet (RDT) and individually packaged in a master pack of six tablets per package.

“Our intent with the launch of this new product is to establish Mango as a legitimate competitor armed with the biotechnology behind Tadalafil and Sildenafil, both of which are the two runaway winners in the ED space over the past two decades,” noted Jacob Cohen, CEO and Co-Founder of MangoRx. “The ED market has already proven to be big enough to accommodate multiple competing products. Some people like Pepsi and others prefer Coca-Cola. Tadalafil and Sildenafil are both effective biotech solutions and we believed it was important to make both options available in order to capture additional market share and not exclude potential customers based on personal preferences.”

MGRX Company’s Co-Founder and CEO, Jacob Cohen, along with the MangoRx family, including Company officials and members of the executive management team, rang the Nasdaq Closing Bell on Thursday, May 18, 2023. Since then, MGRX has been on a roll to promote its flagship product.

MGRX is currently trading at $1.60 range. Considering the public offering was priced at $4 per share there could be a huge upside potential for this NASDAQ listed stock. 

In the stock market today, a few intriguing companies have shown significant movement.

First on our list is Nutex Health Inc. (NUTX). Its current share price stands at $0.465, showcasing an impressive rise of $0.04, or a 10.06% increase. As of 12:14 PM EDT, the trading volume was 6.31 million, notably higher than their average volume of 2.06 million. The corporation boasts a market capitalization of $305.3 million.

Next, we have LumiraDx Limited (LMDX), with its shares priced at $0.4286. This is a surge of $0.08 or 22.46%. As of 12:13 PM EDT, the trading volume was 18.86 million, quite a leap from an average volume of 233.66 thousand. LumiraDx has a market capitalization of $288.59 million.

One major standout today is Advanced Health Intelligence Ltd. (AHI), which saw an astronomical jump in its share price to $1.77, up by $1.03. This equates to a whopping increase of 139.19%. The trading volume at 12:14 PM EDT stood at 76.39 million, significantly above their average of 3.87 million. The market capitalization for Advanced Health Intelligence currently sits at $58.04 million.

Lastly, Mullen Automotive, Inc. (MULN) also experienced notable growth. The shares are priced at $0.1927, up by $0.03 or 20.06%. The trading volume was an impressive 297.48 million, dwarfing their average volume of 46.32 million, as of 12:14 PM EDT. Mullen Automotive has a market capitalization of $46.94 million.

These sudden movements underscore the ever-changing nature of the stock market, which makes it all the more crucial for investors to stay on top of these shifts. Be sure to check back regularly for the latest updates and trends.

Disclaimer: Please ensure to fully read and comprehend our disclaimer found at A payment of $4,500 was received by from Bullyzeye Media LLC for content distribution on MGRX, from 06/12/2023 to 07/07/2023. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated.Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person’s use of or access to this content. Source:

Leave a Reply

Your email address will not be published. Required fields are marked *